Modulation of Intra-alveolar Fibrin Deposition by the Alveolar Epithelium in Acute Lung Injury: Clinical and Experimental Evidence

Lorraine B. Ware,Julie A. Bastarache,Ling Wang,Michael A. Matthay
2012-01-01
Proceedings of the American Thoracic Society
Abstract:Integrins avb3 and avb5 Reciprocally Regulate Pulmonary Endothelial Barrier Function through Differential Effects on the Actin Cytoskeleton George Su1,2, Nanyan Wu1, Amha Atakilit1, Jiyeun Kate Kim1, and Dean Sheppard1,2 Lung Biology Center, Division of Pulmonary and Critical Care Medicine, University of California at San Francisco, San Francisco, California We have shown the integrin avb5 to be a central regulator of lung vascular permeability and pulmonary endothelial barrier function—both considered pathologic hallmarks of acute lung injury (ALI). avb5 co-localizes with the closely related integrin, avb3, at focal adhesions in pulmonary endothelial cells, and both integrins recognize overlapping ligands. Despite these similarities, inhibition of avb3 and avb5 have strikingly different effects on agonist-induced pulmonary endothelial permeability: inhibition of avb3 dramatically enhances increased permeability, whereas inhibition of avb5 prevents increased permeability. These integrins also have dramatically different effects on reorganization of the actin cytoskeleton in these cells. Blockade of avb5 inhibits agonist-induced formation of actin stress fibers, whereas blockade of avb3 specifically inhibits increases in cortical actin organization induced by sphingosine-1 phosphate and constitutively active Rac1. These observations suggest that avb3 and avb5 differentially regulate the pulmonary endothelial permeability response to edemagenic agonists through distinct effects on the actin cytoskeleton. Optimal therapies targeting integrin avb5 for the treatment and/or prevention of ALI may thus be critically dependent on the development of selective antagonists that do not target the closely related integrin avb3. Conflict of Interest Statement: G.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.A. is a co-owner (with D.S.) of a filed patent (pending) covering blockade of integrin avb5 for the treatment of acute lung injury. J.K.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.S. and A.A. are co-owners of a filed patent (pending) covering blockade of integrin avb5 for the treatment of acute lung injury. He has had a sponsored research agreement with Biogen Idec to cover work on anti-integrin antibodies and acute lung injury for $150,000/year (total costs) since January 2002. UCSF co-owns all intellectual property of UCSF faculty, including the pending patent described above. The institution also collects indirect costs on the sponsored research agreement with Biogen Idec, described above. (Received in original form November 13, 2007; accepted in final form November 16, 2007) Funded by NHLBI HL083950 (D.S.) and 1K08HL083097-01A1 (G.S.). Correspondence and requests for reprints should be addressed to George Su, M.D., 1550 4th Street, Room 545, San Francisco, CA 94158. E-mail: george.
What problem does this paper attempt to address?